BioSpace News Archive

BioLife Plasma Services, part of the global biopharmaceutical company Takeda Pharmaceutical Company Limited, today announced the opening of a new plasma collection center in North Las Vegas to collect standard plasma from healthy donors.

Massive blocks of genes—inherited together ‘plug and play’ style—may play a larger role in evolutionary adaption than previously thought, according to new research in Nature.

‍For the first time since 2009, consensus guidelines for vancomycin dosing were published in March 2020 by four pharmacy and infectious disease professional societies.

Magnolia Medical announced today the launch of the new Steripath® Gen2 Initial Specimen Diversion Device® with integrated syringe.

New COVID-19 modeling data released by PolicyLab at Children’s Hospital of Philadelphia forecast a deteriorating situation across most U.S. states over the next four weeks, showing little effect thus far of local masking mandates and suggesting the need for a nationwide strategy focused on increased social distancing.

Acer Therapeutics Inc. (Nasdaq: ACER), today announced data from a food effect study in healthy volunteers showing that administration of ACER-001 in a fasted state increased systemic exposure of phenylbutyrate (PBA), phenylacetate (PAA) and phenylacetylglutamine

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for imsidolimab, the company’s proprietary anti-interleukin-36 receptor (IL-36R) antibody, for the treatment of patients with GPP.

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it and longtime partner, Merck (known as MSD outside the US and Canada) have signed a new license agreement granting Merck the right to develop additional multispecific antibody therapeutic candidates using Zymeworks’ Azymetric™ and EFECT™ platforms.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the appointment of Deborah H. Telman as General Counsel for Organon & Co., its intended spinoff of its women’s health, legacy brands and biosimilars businesses.

Biogen Inc. (Nasdaq: BIIB) today announced that positive results from a Phase 1/2 study of tofersen (BIIB067) for the potential treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS) were published in TheNew England Journal of Medicine.